Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets.
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products.
Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.
It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products.
Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.
It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.
Location: United Kingdom, England, Cambridge
Employees: 11-50
Total raised: $67M
Founded date: 2016
Investors 3
| Date | Name | Website |
| 02.05.2022 | British Pa... | britishpat... |
| 08.03.2022 | Flerie Inv... | flerie.com |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.03.2022 | Series B | $67M | - |
Mentions in press and media 34
| Date | Title | Description |
| 12.04.2023 | Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma | Microbiotica announces clinical trial collaboration with MSD to evaluate MB097 in combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in melanoma Microbiotica, a leader in discovering and developing microbiome-based ther... |
| 07.11.2022 | Microbiotica — unlocking the microbiome as a multi-therapeutic modality | Microbiotica — unlocking the microbiome as a multi-therapeutic modality Microbiotica’s platform makes it a leader in precision clinical discovery of novel microbiome-based therapeutics and biomarkers. With the platform validated at scale, a... |
| 09.09.2022 | Bicycle Therapeutics puts Life Sciences in the vanguard as Business of the Year | Bicycle Therapeutics puts Life Sciences in the vanguard as Business of the Year Business Weekly article Life sciences pioneer Bicycle Therapeutics was last night named as champion company at the Business Weekly Awards at Queens’ College in ... |
| 09.09.2022 | Bicycle Therapeutics, PragmatIC, Microbiotica all winners at the Business Weekly Awards | Bicycle Therapeutics puts Life Sciences in the vanguard as Business of the Year Business Weekly article Life sciences pioneer Bicycle Therapeutics was last night named as champion company at the Business Weekly Awards at Queens’ College in ... |
| 27.04.2022 | £225m raised for Cambridge Innovation Capital’s Fund II | £225m raised for Cambridge Innovation Capital’s Fund II Cambridge Independent article | By Mike Scialom Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses... |
| 05.04.2022 | Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic | Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic Collaboration with US-based non-profit underlines potential of Company’s ulcerative colitis work Microbiotica, a leading player in micr... |
| 15.03.2022 | Top European funding rounds Closed in February 2022 | Top European funding rounds Closed in February 2022 Vestbee article | By Konrad Koncerewicz, Head of VC & Startups We have already presented interesting regional CEE startups that closed funding rounds in February. Today, we are going t... |
| 08.03.2022 | Microbiotica picks up £50M | Microbiotica has raised a £50 million Series B led by Sweden's Flerie Invest and Tencent. The UK-based biotech company will use the capital to fund clinical trials for its two lead microbiome-based therapeutics. View details |
| 08.03.2022 | CIC participates in Microbiotica’s £50m Series B financing to advance microbiome-based therapeutics | CIC participates in Microbiotica’s £50m Series B financing to advance microbiome-based therapeutics 08-03-2022 Cambridge Innovation Capital participates in Microbiotica’s £50m Series B financing to advance microbiome-based therapeutics.Larg... |
| 07.03.2022 | Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics | Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series... |
Show more